SharpyDr. Reddy's Semaglutide: Brazil Approval, Canada, Price
Dr. Reddy's semaglutide is a generic copy of Ozempic made by Dr. Reddy's Laboratories of India. On November 5, 2026, the company said Brazil's regulator ANVISA approved it for adults with type 2 diabetes, adding Brazil to Canada (sold since May 15, 2026) and India (sold as Obeda since March 2026). It is not approved or sold in the United States. If you take any semaglutide, Sharpy helps you hit your protein target and keep your muscle while you lose fat.
What is Dr. Reddy's semaglutide, and can you get it? It is a generic copy of Ozempic made by Dr. Reddy's Laboratories, and as of November 5, 2026, it is approved in Brazil, Canada and India, but not in the United States. Brazil is the newest market. That morning, the company said ANVISA, Brazil's health regulator, had approved its semaglutide injection for adults with type 2 diabetes.
The drug inside is the same: semaglutide, the GLP-1 medicine in Ozempic and Wegovy. What changes is the maker, the pen, the box and the price. Here is where it is sold, what is known about price, the recalls in Canada, and what it means for US readers.
Dr. Reddy's semaglutide at a glance
| Country | Status | Date | Name and strengths | Approved use |
|---|---|---|---|---|
| Brazil | Approved, launch date not announced | ANVISA approval announced November 5, 2026 | Semaglutide injection, 2 mg/1.5 mL and 4 mg/3 mL pens | Adults with type 2 diabetes |
| Canada | Sold in pharmacies | Approved April 28, 2026; launched May 15, 2026 | Semaglutide Injection, 2 mg pen (0.25 or 0.5 mg doses) and 4 mg pen (1 mg doses) | Adults with type 2 diabetes |
| India | Sold in pharmacies | Shot launched March 2026; tablet launched May 2026 | Obeda (shot and tablet) | Type 2 diabetes |
| United States | Not approved, not sold | None | None | None |
All three approvals are for type 2 diabetes, like Ozempic. None of them is a copy of Wegovy for weight loss.
Dr. Reddy's semaglutide in Brazil: what was approved
According to the company's statement, reported by PTI on November 5, 2026:
- Who it is for: adults with type 2 diabetes that is not well controlled, along with diet and exercise. It can be used alone when metformin is not a fit, or with other diabetes medicines.
- The pen: a pre-filled pen that holds several doses, in 2 mg/1.5 mL and 4 mg/3 mL sizes, used once a week.
- The launch: Dr. Reddy's plans to sell it with Aché, a Brazilian drugmaker. No launch date or price was given.
- The market: the company put the Brazilian semaglutide market for diabetes at about $244.6 million and said Brazil has 16.6 million adults aged 20 to 79 living with diabetes.
Dr. Reddy's is not the first generic in Brazil. Sandoz and Adalvo's Owozy was approved on July 29, 2026. Our generic semaglutide guide has the full country chart.
Dr. Reddy's semaglutide in Canada
Canada was the first G7 country to approve a generic semaglutide, and Dr. Reddy's was first in line. Health Canada issued its approval on April 28, 2026, and the company launched on May 15, 2026.
The Canadian product is approved for adults with type 2 diabetes, with diet and exercise. Each pen holds semaglutide at 1.34 mg/mL. The 2 mg pen gives 0.25 mg or 0.5 mg doses, and the 4 mg pen gives 1 mg doses. You need a prescription, and pharmacy prices vary by province and store. Dr. Reddy's has not published a Canadian price.
The Dr. Reddy's semaglutide recall
"Dr reddy semaglutide recall" is one of the most searched phrases about this drug, for a good reason. In August 2026, Health Canada posted two Type II recalls:
| Recall | Date | Lots | Problem |
|---|---|---|---|
| RA-82477 | August 12, 2026 | 7000544C (DIN 02567806) | A 4 mg pen inside a box labeled 2 mg |
| RA-82537 | August 27, 2026 | 7000544, 7000545, 7000546 (DIN 02567806); 7000542, 7000543, 7000624, 7000628, 7000629 (DIN 02567814) | An impurity out of specification |
A Type II recall means a product could cause temporary health problems, or the chance of serious harm is low. If your lot is on the list, do not use it, and call your pharmacist and prescriber before you stop or switch. Our semaglutide recall guide lists every 2026 recall in one place.
Dr. Reddy's semaglutide in India: Obeda
In India, Dr. Reddy's sells semaglutide under the brand name Obeda. The shot launched in March 2026, right after the Indian patent ran out, and was priced at about 4,200 rupees a month for both pen strengths. That was well below Novo Nordisk's brands but above some rival generics. In May 2026, the company added an Obeda tablet, an oral semaglutide, at 99 rupees per tablet. The tablet is sold in India only.
Is Dr. Reddy's semaglutide the same as Ozempic?
It has the same active drug and the same weekly dosing as Ozempic, and each regulator judged it equal to the brand before approving it. The pen, inactive parts and packaging can differ. So:
- Ask your pharmacist to show you the new pen before the first dose.
- Check the strength on the box and the pen every time. The August mix-up was a 4 mg pen in a 2 mg box.
- Do not count clicks to build a custom dose. Use the pen only as its instructions say, at the dose your prescriber set.
- Tell your prescriber about any new side effects.
Side effects should match Ozempic's. Nausea, vomiting, diarrhea and constipation are the most common. Our semaglutide dosage chart shows the label doses for each brand.
What this means if you live in the US
No generic semaglutide has final FDA approval as of November 5, 2026, and Dr. Reddy's does not sell it here. Apotex holds the only tentative FDA approval for a generic Ozempic, and Novo Nordisk has reported that its main US patent runs into 2032. Bringing prescription drugs from Canada or India is generally not allowed for individuals.
So a US website that sells "Dr. Reddy's semaglutide" or "Obeda" is not selling an FDA-approved product. The FDA has warned about fake and unapproved GLP-1 drugs, and our compounded GLP-1 guide explains how to spot them. Lower US prices are coming another way: Novo plans a new $675 list price in 2027, covered in our Ozempic price cut guide.
A cheaper pen does not protect your muscle
A generic changes the price, not what the drug does to your body. Semaglutide cuts your appetite, and when you eat less, some of the weight you lose can be muscle unless you eat enough protein and lift. Sharpy gives you one protein target based on your weight, one 20-minute strength workout and one Shape Score a day, so more of the loss comes from fat. Our protein target guide shows how the number is set.
The bottom line
Dr. Reddy's semaglutide is a generic Ozempic copy for type 2 diabetes. It is sold in Canada and India (as Obeda), approved in Brazil as of November 5, 2026, and not available in the US. Canadian users should check their lot numbers against the August 2026 recalls. Whatever brand is in your pen, keep your protein and strength habits steady with Sharpy so the weight you lose stays fat, not muscle.
Sources
- Dr Reddy's gets regulatory approval to market generic semaglutide injection in Brazil, PTI via Daily Excelsior (November 5, 2026)
- Dr. Reddy's receives Brazil marketing authorization for generic semaglutide injection, InvestyWise (November 5, 2026)
- Dr. Reddy's: launch of generic semaglutide injection in Canada (May 15, 2026)
- Dr. Reddy's becomes first to secure Health Canada nod for generic semaglutide injection, Indian Pharma Post
- Dr. Reddy's launches India's first DCGI-approved semaglutide injection Obeda, Indian Pharma Post
- Dr. Reddy's launches semaglutide at 4,200 rupees a month, NewsBytes
- Dr Reddy's launches oral semaglutide tablets at 99 rupees per pill in India, Business Today (May 20, 2026)
- First wave of generic Ozempic approvals in South America, Pearce IP (July 29, 2026)
- Health Canada Recalls and Safety Alerts
- Apotex: first US FDA tentative approval for a generic Ozempic (April 10, 2026)
- FDA's concerns with unapproved GLP-1 drugs used for weight loss
Questions people ask
What is Dr. Reddy's semaglutide?
It is a generic version of semaglutide, the drug in Ozempic, made by Dr. Reddy's Laboratories, a drug company based in Hyderabad, India. It is a once-weekly shot in a pre-filled pen, approved for adults with type 2 diabetes in the countries where it is sold.
Is Dr. Reddy's semaglutide approved in Brazil?
Yes. On November 5, 2026, Dr. Reddy's said ANVISA, Brazil's health regulator, granted marketing authorization for its generic semaglutide injection for adults with type 2 diabetes. It will come in 2 mg/1.5 mL and 4 mg/3 mL pens. The company plans to launch with the Brazilian drugmaker Aché but has not given a launch date.
Is Dr. Reddy's semaglutide available in Canada?
Yes. Health Canada approved it on April 28, 2026, and Dr. Reddy's launched it on May 15, 2026. It was the first generic semaglutide approved in Canada. It comes in a 2 mg pen for 0.25 mg or 0.5 mg doses and a 4 mg pen for 1 mg doses, and you need a prescription.
What is the Dr. Reddy's semaglutide recall?
In August 2026, Health Canada posted two Type II recalls of Dr. Reddy's semaglutide pens. One lot had a 4 mg pen packed in a box labeled 2 mg. Several other lots were recalled because an impurity was out of specification. If you have a pen, check your lot number against the Health Canada notice and ask your pharmacist.
Can you buy Dr. Reddy's semaglutide in the US?
No. As of November 5, 2026, no generic semaglutide has final FDA approval, and Dr. Reddy's does not sell semaglutide in the US. Any US website selling "Dr. Reddy's semaglutide" is not selling an FDA-approved product.
Should I count clicks on a Dr. Reddy's semaglutide pen?
Only use the pen the way the product monograph and your pharmacist show you, at the dose your prescriber chose. Do not count clicks to make a custom dose. A pen used outside its instructions can give a wrong dose, and the August 2026 mix-up of a 4 mg pen in a 2 mg box shows why you should check the label every time.